Published Date: 08 Mar 2023
This review compared the effectiveness of entecavir and tenofovir in reducing relapses and mortality after treatment for HBV-related hepatocellular carcinoma.
Read Full NewsCuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.
Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.
New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors
Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia
Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA
1.
For incarcerated people, study shows gaps exist in quality of cancer care
2.
Some low-grade prostate cancers carry higher risks than biopsy suggests
3.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
4.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
5.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
1.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Thyroidectomy & Survival: Highlights from ASCO 2025 and Current U.S. Findings
4.
The Unseen Danger of Anal Cancer: How to Protect Yourself
5.
IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
2.
Current Scenario of Cancer- The Incidence of Cancer in Men
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation